Are you looking for the latest pharma news on leading pharmaceutical companies in India? Strides Pharma Science Limited continues to set new benchmarks in the pharma manufacturing sector, reporting its best-ever quarterly EPS and operational performance for Q2FY26.
With a strategic focus on regulated markets and innovative product development, Strides Pharma stands out among the top pharmaceutical companies delivering sustainable growth and profitability.
Contents
- 1 Q2FY26 Financial Highlights: Exceptional Growth in Profitability and Margins
- 2 H1FY26 Overview: Consistent Performance Across Six Months
- 3 Segmental Performance: Regulated Markets Drive Strong Results
- 4 Emerging Markets: Africa, LATAM, MENA, APAC
- 5 Balance Sheet and Financial Discipline
- 6 Outlook: Focus on Sustainable Growth and Innovation
- 7 About Strides Pharma Science Limited
Q2FY26 Financial Highlights: Exceptional Growth in Profitability and Margins
Strides Pharma’s consolidated revenue for Q2FY26 reached ₹12,208 million, marking a 4.6% year-on-year (YoY) growth. The company’s absolute gross margin increased to ₹7,056 million, representing an impressive 14.6% YoY rise. The gross margin percentage improved by 500 basis points, hitting 57.8%.
This demonstrates Strides’ operational efficiency and commitment to maximizing returns even during challenging market conditions. EBITDA for the quarter was ₹2,316 million (a 25.4% YoY increase), and the EBITDA margin improved to 19.0%, up by 320 basis points YoY.
Most notably, Strides achieved an operational Profit After Tax (PAT) of ₹1,403 million in Q2FY26, surging by 84.3% compared to last year. Operational EPS for the quarter came in at ₹15.2, up 83.8% YoY, signaling the company’s optimal earnings performance and effective cost management. Reported PAT stood at ₹1,315 million, further reflecting strong financial discipline.
H1FY26 Overview: Consistent Performance Across Six Months
For the half-year ended September 2025, Strides Pharma Science Limited posted total revenue of ₹23,406 million, up 5.4% YoY. The gross margin expanded to ₹13,810 million, and the EBITDA for H1FY26 reached ₹4,496 million (a robust 20% increase from H1FY25). Operational PAT for the half-year hit ₹2,543 million with an EPS of ₹27.6, growing by more than 82% YoY.
Such sustained and consistent growth highlights Strides’ position as a top performer in India’s pharmaceutical manufacturing industry, particularly among companies focusing on regulated and global markets.
Segmental Performance: Regulated Markets Drive Strong Results
United States Market
Strides maintained a steady revenue stream of $73 million from its US operations during Q2FY26, recording a 2% YoY growth despite intense competition in the generics space. The company launched three new products in H1FY26, strengthening its commercialized portfolio to 70 products.
Impressively, Strides continues to hold a top-three market position for 37 major products in the US, contributing roughly 75% of total US revenue. With over 230 ANDAs filed and 215+ approvals granted as of July 2025, Strides is well-positioned to achieve its generics revenue target of $400 million by FY27-28.
Other Regulated Markets: Europe and Beyond
Revenue from other regulated markets stood at $44 million for Q2FY26, reflecting robust 16% YoY growth. Strides’ expansion in Europe has been fueled by new large Pan-EU partnerships and the momentum of B2B collaborations.
The UK business remained stable, while upcoming launches signal further growth potential in H2FY26. Strategic customer advocacy and dependable supply chains have allowed Strides to broaden its reach and strengthen its portfolio in these regions.
Emerging Markets: Africa, LATAM, MENA, APAC
Q2FY26 revenue from growth markets was ₹1,468 million ($17 million), marking a 7% increase YoY. Africa operations led this growth, supported by new product launches. Access market revenue came in at ₹609 million ($7 million), down 25% due to challenges stemming from donor funding environments.
Strides is actively focusing on regulatory filings and building long-term channel partnerships to accelerate growth in these emerging territories.
Balance Sheet and Financial Discipline
A notable achievement for Strides in Q2FY26 was the reduction of net debt by ₹469 million, even as the company managed ongoing capital investments and navigated currency headwinds.
At the end of September 2025, net debt stood at ₹14,489 million, reflecting prudent financial management and strong cash flow generation. The debt-to-equity ratio and net debt-to-EBITDA metrics also showed improvement, further reinforcing Strides’ reputation for financial discipline and stable governance.
Outlook: Focus on Sustainable Growth and Innovation
Strides Pharma Science Limited is committed to delivering long-term, sustainable growth by focusing on profitability, balance sheet strength, and operational excellence. The company is investing in “Beyond Generics” products such as control substances nasal sprays and 505(b)(2) products, including the recent USFDA filing of its first nasal spray.
This forward-looking strategy aligns Strides Pharma with high-growth segments in the international pharmaceutical market and ensures a strong competitive advantage for years to come.
Note: Read the Official Press Release of Strides Pharma on their Website
About Strides Pharma Science Limited
Strides is a global pharmaceutical company headquartered in Bengaluru, India, listed on the BSE (532531) and NSE (STAR). The company has manufacturing facilities in India, Italy, Kenya, and the United States, specializing in “difficult to manufacture” products and serving more than 100 countries.
Strides’ strategic “in Africa for Africa” approach, coupled with its institutional business for donor-funded markets, enables it to deliver impactful solutions and foster global health partnerships.
Stay updated with Strides Pharma’s quarterly news, job opportunities in pharmaceutical manufacturing, and the latest trends in India’s pharma sector for 2025. Bookmark this page and follow Strides’ journey to innovative leadership in global healthcare solutions.